IP Group NAV Crosses One Billion Amid Pfizer Royalty Gains

IP Group Plc reported that its net asset value per share rose 3.2% to 114p in the first half of 2026, pushing total NAV above the £1 billion mark. Chief Executive Greg Smith noted that the value had subsequently climbed to approximately 117p by September 11, primarily reflecting a higher valuation for its listed holding in Oxford Nanopore. The company also generated £69 million in cash proceeds during the period, exceeding the total recorded for all of 2025.

The increase in asset value was largely driven by IP Group’s royalty interest in Pfizer’s obesity treatment programs. The carrying value of this interest increased by £27 million to just over £150 million after Pfizer’s berobenatide and amylin combination therapy advanced into a Phase IIb clinical trial. According to CFO David Baynes, the valuation adjustment resulted from raising the estimated probability of success for the combination therapy from 25% to 39%.

Cash Realizations Exceed Prior Year Totals

IP Group generated £69 million in cash proceeds during the first six months, a figure that surpassed the total proceeds recorded for the entirety of 2025. Including a further £17 million received after the period end, year-to-date proceeds reached approximately £86 million. These exits included positions in Hinge Health, Monolith, and Centessa. Management has stated a target of achieving £250 million in total realizations by the end of 2027.

The company is currently evaluating how to convert approximately £50 million of available proceeds into shareholder returns. Smith indicated that while the default strategy is to retain the Pfizer royalty interest to collect payments if the programs proceed as expected, the firm would consider partially monetizing the position if an attractive proposal emerged. This approach allows IP Group to balance immediate liquidity with long-term upside potential.

Pfizer Obesity Program Drives Valuation Shift

The largest contributor to the half-year valuation gain was the advancement of Pfizer’s obesity pipeline. Pfizer reported positive data from its lead berobenatide program, citing competitive weight-loss efficacy and favorable tolerability. The company is progressing ten Phase III studies this year, with patient recruitment for essentially all of them close to completion. Pfizer is targeting a potential launch in 2028, which supports the probability-weighted valuation model used by IP Group.

IP Group also holds exposure to other Pfizer obesity programs, including an amylin monotherapy and earlier-stage oral, prodrug, and GIPR programs. Baynes noted that two Phase I assets were not currently assigned a value in the company’s model because they remain too early-stage. The lead berobenatide monotherapy program maintained its valuation as it continues in Phase III trials, while the combination therapy drove the majority of the financial increase.

Portfolio Fundraising Validates External Interest

Portfolio companies raised more than £500 million from third-party investors during the half. IP Group contributed approximately 5% of that capital, with the remainder sourced from external parties. Smith described this fundraising activity as external validation of the portfolio’s trajectory. This capital injection supports the ongoing operations and development of the science and technology assets held by the group.